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Communicated by Michael Dean
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. While
cigarette smoking is a major cause of COPD, only 15% of smokers develop the disease, indicating major genetic
influences. The most widely recognized candidate gene in COPD is SERPINA1, although it has been suggested
that SERPINA3 may also play a role. To detect cryptic genetic variants that might contribute to disease, we
identified 15 SNP haplotype tags from high-density SNP maps of the two genes and evaluated these SNPs in the
largest case-control genetic study of COPD conducted so far. For SERPINA1, six newly identified haplotypes
with a common backbone of five SNPs were found to increase the risk of disease by six- to 50-fold, the highest
risk of COPD reported to date. In contrast, no haplotype associations for SERPINA3 were identified.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD [MIM]
606963]) is the sixth leading cause of death in the Western world
[Gulsvik, 1999]. Although cigarette smoking is the major cause of
COPD, only 15% of smokers develop the disease, which indicates
that there may be genetic influences [Fletcher and Peto, 1977].
Protease–antiprotease imbalance is a widely supported hypothesis
for the pathogenesis of COPD. The major circulating antipro-
teases, which have arisen by gene duplication, are SERPINs A1
[MIM] 107400] and A3 [MIM] 107280] [Brantly et al., 1988].
Severe deficiency of SERPINA1 accounts for about 2% of patients
with COPD with a history of cigarette smoking, but the role of
SERPINA3 remains to be clarified [Mittman et al., 1973]. Based
on family studies, the estimated relative risk for genetic
susceptibility to COPD is about 3 [DeMeo and Silverman,
2003]. Deficiency of SERPINA1 (more commonly known as
a-1-antitrypsin) is the only recognized genetic factor contributing
to disease. This manifests mainly in cigarette smokers, emphasizing
the importance of genetic and environmental factors. The overall
risk for COPD in cigarette smokers is increased approximately up
to 20-fold in protease inhibitor (Pi) Z homozygotes of the
SERPINA1 gene, which occurs in about 1/2,000–3,000 individuals
of northern European descent. The highest frequencies are
observed in Scandinavia; however, not all Pi Z homozygotes
develop COPD [Silverman et al., 1998]. A recent meta-analysis
concluded that carriers of the Z variant have an increased odds
ratio of 2.31 for COPD [Hersh et al., 2004].
The association of SERPINA1 deficiency with COPD has led to
the protease–antiprotease imbalance theory of disease causation,
which is supported by a number of experimental models [Karlinsky
and Snider, 1978; Cavarra et al., 1996]. Briefly, this states that
when neutrophils are recruited to the lung during an inflammatory
process, they are primed to release the serine proteases neutrophil
elastase (NE) and cathepsin G (CG). In animal models these
proteases have been shown to be essential for killing bacteria
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[Reeves et al., 2002]. If sufficient inhibitor is not present,
uninhibited enzyme activity can destroy the connective tissue of
the lung, resulting in loss of normal tissue architecture and
function. Given the role of this gene in COPD, there is a high prior
probability of cryptic variation in the SERPINA1 gene contribut-
ing to this disease. Genetic studies of SERPINA1 variation other
than the Z variant have yielded controversial results, which have
been attributed to small sample sizes and a lack of adequate cover-
age of the gene [Poller et al., 1990; Sandford et al., 1997]. Simi-
larly, a number of small case-control studies reported inconsistent
results on the role of the other major circulating antiproteinase,
SERPINA3 (more commonly known as a-1-antichymotrypsin), in
COPD [Poller et al., 1992; Sandford et al., 1998].
In the largest case-control study reported to date, we screened
1,018 COPD patients and 911 nondiseased control smokers
recruited at six European centers for nine SNPs that define the
common haplotypes for the SERPINA1 gene, plus the Pi S variant,
which is the most common known mutation that causes mild
deficiency in Europeans, and five SNPs that define common
haplotypes of the SERPINA3 gene.
MATERIALSANDMETHODS
Subjects
The numbers of cases and controls recruited from each center
were as follows: Barcelona, 70 controls and 138 cases; Bristol, 151
controls and 129 cases; Dublin, 195 controls and 196 cases;
Edinburgh, 81 controls and 169 cases; Leiden, 216 controls and
188 cases; and Pisa, 198 controls and 198 cases. Approval for the
study was obtained from the appropriate committees at each
recruitment center (el Comite de Investigacion del Hospital
Clinic, Barcelona; Southmead Local Research Ethics Committee,
Bristol; St. Vincent’s Hospital Ethics and Medical Research
Committee, Dublin; Lothian Research Ethics Committee, Edin-
burgh; de Commissie Medische Ethiek van het LUMC, Leiden;
and il Comitato Etico, Azienda Ospedaliera Pisana, Pisa).
Informed consent was obtained from all subjects.
The criteria for patient recruitment were a firm clinical
diagnosis of stable COPD, airflow limitation as indicated by
FEV1r70% normal predicted values (calculated as recommended
[Crapo et al., 1981] and FEV1/FVC o70%, no significant
reversibility on bronchodilation [Brand et al., 1992], and a
smoking history of Z20 pack-years. Patients were excluded from
the study if they had an established diagnosis of asthma,
established obstructive syndrome or lung cancer, a history of
atopy, known SERPINA1 deficiency, or a serum SERPINA1 level
of o1.0 g/L. They were also excluded if they had experienced an
acute exacerbation in the 4 weeks preceding assessment for the
study. Only white Caucasian patients were recruited.
Control subjects were recruited at each center to match COPD
patients for age and gender. All controls were current or
ex-smokers with a smoking history similar to that of the COPD
patients. Individuals were excluded if they had a history of chronic
lung disease or atopy, an acute pulmonary infection in the 4 weeks
preceding assessment for the study, known SERPINA1 deficiency,
a serum SERPINA1 level of o1.0 g/L, or a family history of
COPD. Only individuals with no evidence of airflow obstruction
(FEV1 and FVCZ80%, and FEV1/FVC 470%) were included
in the control group. Complete matching of control and COPD
groups was not achieved because a high proportion of smokers
over the age of 65 had evidence of some obstruction in pulmo-
nary function. Even though these individuals did not have
overt symptoms of disease, our strict criteria meant they were
excluded from the study, which reduced the number of available
controls.
The characteristics of each group were as follows, with values
expressed as the mean (SD) when appropriate:
Controls: 63.5% male; age 60.8 (8.9); smoking pack-years 38.6
(17.4); %pred FEV1 95.3 (10.9); FEV/FVC% 77.9 (4.9).
COPD cases: 69.6% male; age 65.8 (8.2); smoking pack-years
48.9 (23.6); %pred FEV1 43.0 (15.3); FEV/FVC% 47.5 (12.2).
Identifying Haplotype-Tagging SNPs and Genotyping
the Study Population
We previously identified nine haplotype-tagging SNPs that
define common haplotypes for SERPINA1 via high-density SNP
mapping [Chappell et al., 2004]. In the current study we also
screened for the Pi S variant (SNP 7) because even though it does
not occur at a frequency of 45%, it is the most common known
deficiency variant in Europeans.
Haplotype-tagging SNPs for the SERPINA3 gene were identi-
fied using a strategy similar to that used for SERPINA1. Briefly,
SNPs were identified and confirmed by bidirectional sequencing of
all exons and 50 flanking regions in 44 samples. SNPs that occurred
at more than 5% were genotyped in 291 samples by the MRC
Geneservice (Babraham, UK) using PCR with fluorescently-
labeled Taqman probes (Vic or Fam labels).
Genotyping of the study population for the SERPINA1 and
SERPINA3 haplotype-tagging SNPs was also carried out at the
MRC Geneservice (Babraham, UK) using PCR with fluorescently-
labeled Taqman probes (Vic or Fam labels). The primer and probe
sequences are available on request. As a quality control measure,
44 samples of known genotype determined by sequencing were
included. These genotypes were unknown to the MRC but were
known at the source. When discrepancies were noted the analysis
was repeated. This resulted in 100% concordance for all the assays.
The SNPs are numbered with respect to the GenBank genomic
DNA sequences AL132708.3 for SERPINA1, and AL049839.3
for SERPINA3.
Analysis of GeneticVariation in Population Groups
Each of the SNPs in SERPINA1 and -A3 were analyzed for
Hardy-Weinberg equilibrium (HWE) using PROC ALLELE in
SAS/Genetics Release 8.2 (SAS Institute Inc., Cary, NC) with hot
fix 82GN03. To examine linkage disequilibrium, the correlation
coefficient between SNP pairs within each gene in cases and
controls was calculated under the assumption of HWE using the
same program.
Allele and Genotype Frequencies in COPD
Cases and Controls
Analysis was performed using PROC CASECONTROL in SAS/
Genetics. Since matching was not completely achieved on
recruitment, we adjusted for any residual confounding due to
age, sex, smoking, and center using logistic regression. This also
gave us an increase in power by accounting for the matched
design. Age was categorized into four groups (o55 years;
55–64 years; 65–69 years; 701 years), and smoking was categorized
as heavy or light based on a definition of heavy smoking that was
center-dependent at an approximate 40th centile cut-point. All
effects were coded as dummy binary variables, and interactions of
age, sex, and smoking with center were included. This approach
was also used to correct haplotype-disease associations (see
below).
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HaplotypeAnalysis
For a full analysis of the relationships between COPD and
the SERPINA1 and -A3 SNPs, we used a staged, haplotype-
based approach. It was first necessary to identify which SNP
groupings within each gene should be subjected to the
haplotype analysis. There are a number of approaches for detecting
haplotype groups in a gene, but all are based on defining a group
as a block of contiguous SNPs [Zhang and Jin, 2003]. The
objective of these methods is to identify haplotype-tagging
SNPs that can be used to reduce the number of SNPs to genotype
while still achieving a large percentage coverage of variation
within the gene. We were interested in identifying haplotypes that
differed in frequency between COPD cases and controls, using
haplotype-tagging SNPs already identified from high-density
mapping of the SERPINA1 and -A3 genes. Since there is no
reason to suspect that disease-associated haplotypes might be
combinations of contiguous SNPs, and there are no proven
shortcut methods for identifying such groupings, we screened all
possible SNP groups in each gene for differences between cases
and controls. This was done by performing an omnibus test [Zhao
et al., 2000] as implemented in SAS/Genetics PROC HAPLO-
TYPE. Exact P-values based on a permutation test were employed.
We used a screening value of 1,000 permutations to initially
choose SNP groups with exact P-valuesr0.017. This ensured that
(based on 0.0099 being the exact 95% lower binomial confidence
limits for 17 out of 1,000) a nominal P-value of o0.01 was
achieved. The P-value was then recalculated for these groups with
10,000 permutations, and the final groups were chosen based on a
P-value of o0.01.
Once SNP groups that were potentially related to COPD were
identified, employing the standard EM algorithm, PROC HAP-
LOTYPE was used to generate all possible haplotype patterns
within these groups and to compare the distributions between
cases and controls. Exact P-values based on 10,000 permutations
were generated.
Haplotypes with a frequency of over 0.5% in cases and controls
combined that differed between cases and controls at the po0.001
level were considered relevant. This ensured that extremely rare
haplotypes were excluded from consideration.
ConfounderAdjustment
Because SNP data are unphased, it is not possible to assign
haplotypes to individuals. PROC HAPLOTYPE uses the expecta-
tion maximization (EM) algorithm to determine the frequency of
each possible haplotype in cases and controls, and performs an
overall significance test [Zhao et al., 2000]. Without haplotype
data at an individual level, however, only a limited confounder
adjustment can be performed using a stratified approach. A
recently described technique, termed haplotype trend regression
(HTR), utilizes regression methods for confounder adjustment by
assigning the probability of having a particular haplotype to each
individual and substituting that probability for the usual 1/0 coded
binary predictor variable of haplotype present or absent [Zaykin
et al., 2002]. However, applying this technique to our data yielded
odds ratios that were severely biased upwards, so we used an
alternative unbiased approach. This approach uses a weighted
logistic regression with the probability of having a particular
haplotype defining the weights (see Supplementary Appendix S1;
available online at www.interscience.wiley.com/jpages/1059-7794/
suppmat). The haplotype probabilities were obtained using
PROC HAPLOTYPE and used to adjust haplotype odds ratios
and significance levels for the effects of center, age, sex, and
smoking. Odds ratios (adjusted and nonadjusted) were based on
the logistic regression and are the odds of disease in those with
a particular haplotype relative to the odds in those without
that haplotype.
Assessment of Population Strati¢cation
To assess the effects of stratification we used data obtained from
screening the same study population for 20 SNPs in four unlinked
genes: g-glutamyl cysteine synthetase catalytic and regulatory
subunits, tumor necrosis factor, and epoxide hydrolase. Allelic
association was first tested for each of the 20 SNPs using 2 2
contingency tables. The individual chi-square test statistics were
summed for the 20 SNPs to give an overall summary chi-square
statistic [Pritchard and Rosenberg, 1999].
MultipleTesting
Given the role of the SERPINA1 gene in COPD, the prior
probability of cryptic genetic variation contributing to disease
would be considered to be high, and as a result the issue of
multiple testing is not as problematic as it is in genomewide scans,
where no a priori assumptions are made. We did not explicitly
account for multiple testing in the calculation of P-values in this
study; rather, we chose to use a stringent P-value and provide
details of the analysis.
RESULTS
Identi¢cation of Haplotype-Tagging SNPs for
SERPINA3
High-density SNP mapping of the SERPINA3 gene identified
five SNPs that occurred with a frequency of 45%. These SNPs
produce six major haplotypes representing almost 100% coverage
of the variation observed in the gene (Table 1).
Allele and Genotype Frequencies in COPD
and Control Populations
The locations of the 10 SERPINA1 and five SERPINA3 SNPs
screened for in the study population are indicated in Figure 1. The
allele frequencies for the minor variant of each of the 10
SERPINA1 and five SERPINA3 SNPs in the control and COPD
groups are shown in Table 2. For ease of presentation, the SNPs are
numbered sequentially relative to the coordinates of the human
genomic DNA sequences AL132708.3 for SERPINA1 and
AL049839.3 for SERPINA3. The position and base change of
each SNP relative to the hepatocyte transcription start site are also
indicated in parentheses. SNP g.135728A4T (SNP 7) of
SERPINA1 is the Pi S variant.
The initial comparison of allele frequencies indicated that
SERPINA1 SNPs 1 and 7 differed significantly between controls
and COPD groups. However, when corrected for smoking, age,
gender, and center, only SNP 1 retained borderline significance
(Table 2).
There were no differences between COPD and control groups in
the frequency of any of the five SERPINA3 SNPs before or after
confounder adjustment (Table 2).
Only minor differences were detected in the frequencies of
SNPs across the six recruitment sites for all 15 SNPs, with the
exception of SERPINA1 SNP 10, which varied from 4.85% in
Edinburgh to 14.18% in Pisa. Previously published data showed
population differences for this SNP, with a higher frequency in
eastern Europe [Samilchuk et al., 1997]. There were, however,
no significant differences in the frequency of this particular SNP
Human Mutation DOI 10.1002/humu
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between the cases (14.18%) and controls (13.26%) in the Pisa
group or for any other population group. All of the SNPs reported
were in HWE in both cases and controls.
The linkage disequilibrium (LD) results for SERPINA1 in the
control group are shown in Table 3, confirming in this large
population the low values of LD that were previously noted in a
smaller group for SERPINA1 [Chappell et al., 2004]. The strength
of LD between SNPs in SERPINA3 is high in comparison to
SERPINA1 (Table 3).
HaplotypeAnalysis
For SERPINA1 the initial analysis identified seven SNP groups
that differed significantly between COPD cases and controls
TABLE 1. Haplotypes of the SERPINA3 Gene inNormal Subjects
g.44695G4T (12799) g.57443G4T (51) g.59569G4A (2076) g.59847A4G (2354) g.64231C4G (6738) Frequency
G G G A C 0.16
G G G A G 0.25
G T G A C 0.04
G T A A C 0.38
G T A A G 0.09
T G G G G 0.08
RareHaplotypes (o1%) o0.01
Numbering is with respect to the GenBank sequence AL049839.3, with numbering with respect to the hepatocyte transcription start site shown
in parentheses.
FIGURE 1. Location of SNPs in SERPINA1and -A3. Shaded boxes represent coding exons (not to scale).
TABLE 2. Allele Frequency ofSERPINA1andSERPINA3 SNPVariants inControls andCOPDSubjects
SNPNo SNP dbSNP reference Control COPD P-valuea CorrectedP-valueb
SERPINA1
1 g.126076T4C (1973) rs8004738 52.2% 48.7% 0.037 0.0294
2 g.126333C4T (1716) ^ 41.4% 44.5% 0.062 0.0528
3 g.128113C4T (65) rs1243160 18.8% 18.5% 0.774 0.5455
4 g.128117G4A (69) rs2854254 37.2% 35.1% 0.188 0.3619
5 g.133789G4A (5741) rs709932 17.0% 17.0% 0.976 0.8276
6 g.135575T4C (7527) rs6647 17.9% 19.6% 0.200 0.1880
7 g.135728A4T (7680) rs17580 3.6% 5.0% 0.035 0.1825
8 g.138147A4C (9995) ^ 26.5% 25.7% 0.576 0.4193
9 g.139425A4G (11377) rs11832 48.2% 47.4% 0.643 0.7070
10 g.139535G4A (11487) ^ 7.7% 7.8% 0.948 0.8418
SERPINA3
1 g.44695G4T (12799) ^ 11.5 11.3 0.836 0.2763
2 g.57443G4T (51) rs1884082 52.1 50.5 0.324 0.7589
3 g.59569G4A (2076) rs4934 49.8 47.3 0.121 0.3991
4 g.59847A4G (2354) ^ 12.1 12.2 0.896 0.4972
5 g.64231C4G (6738) rs8004988 44.5 43.0 0.353 0.1138
Numbering is with respect to the GenBank sequenceAL132708.3 for SERPINA1 and AL049839.3 for SERPINA3, with numbering with respect to the
hepatocyte transcription start site shown in parentheses.
aCrude P-values.
bP-values corrected by logistic regression for age, gender, center, and smoking.
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(2/5 SNPS, 2/6 SNPs, 2/7 SNPs, and 1/8 SNPs (Table 4)). There
were no significant (Po0.01) SNP groups of sizes 10, nine, four,
three, or two. It was of note that none of the groups consisted of
contiguous SNPs only.
The second stage of analysis for SERPINA1 identified six
haplotypes that were risk factors for COPD. These consisted of
one 5-SNP, two 6-SNP, two 7-SNP, and one 8-SNP haplotypes
(Table 5). It was of note that regardless of haplotype size, the SNP
variant present at each SNP site was the same.
For SERPINA3 the omnibus analysis indicated that no SNP
group differed significantly (Po0.01) between COPD cases and
controls. As recommended by SAS Institute Inc. (Cary, NC), no
further haplotype analysis was carried out on this gene.
Population Strati¢cation
The overall chi-squared value for the 20 SNPs in unrelated
genes of 8.584 with 20 degrees of freedom was not significant
(P5 0.9872). We therefore have no evidence of stratification in
our data [Pritchard and Rosenberg, 1999]. Our use of cases and
controls for each recruitment center also minimized the potential
for stratification.
MultipleTesting
The consistency of the SERPINA1 SNP combinations that
contribute to risk, combined with the strength of the association
and the absence of any association with SERPINA3 haplotypes,
make it very unlikely that these results were a spurious outcome of
multiple testing.
DISCUSSION
We identified six haplotypes in SERPINA1 that were risk factors
for COPD (Table 5). They included one 5-SNP, two 6-SNP, two
7-SNP, and one 8-SNP haplotypes, all of which have a common
5-SNP backbone. This is suggestive of a basic 5-SNP risk-associated
TABLE 3. LinkageDisequilibriumCorrelationCoe⁄cients forSERPINA1andSERPINA3 inControls
SNPNos. 2 3 4 5 6 7 8 9 10
SERPINA1
1 0.855 0.156 0.188 0.211 0.206 0.118 0.158 0.356 0.103
2 ^ 0.247 0.094 0.271 0.047 0.096 0.229 0.247 0.136
3 ^ ^ 0.621 0.198 0.026 0.095 0.234 0.313 0.281
4 ^ ^ ^ 0.236 0.067 0.151 0.083 0.046 0.107
5 ^ ^ ^ ^ 0.205 0.075 0.660 0.354 0.131
6 ^ ^ ^ ^ ^ 0.091 0.273 0.220 0.138
7 ^ ^ ^ ^ ^ ^ 0.095 0.174 0.001
8 ^ ^ ^ ^ ^ ^ ^ 0.497 0.174
9 ^ ^ ^ ^ ^ ^ ^ ^ 0.279
SERPINA3
1 0.337 0.314 0.910 0.397
2 ^ 0.921 0.368 0.571
3 ^ ^ 0.353 0.506
4 ^ ^ ^ 0.402
TABLE 4. SERPINA1SNPGroups Related toCOPDat Final Po0.01 (OmnibusTest)
No. of SNPs
in group 1 2 3 4 6 7 8 10
Exact P-value
(1,000 permutations)
Exact P-value
(10,000 permutations)
5 1 3 4 7 10 0.004 0.0059
5 1 3 4 8 10 0.006 0.0060
6 1 3 4 7 8 10 0.003 0.0038
6 1 2 3 4 8 10 0.007 0.0044
7 1 2 3 4 7 8 10 0.006 0.0039
7 1 2 3 4 6 8 10 0.013 0.0091
8 1 2 3 4 6 7 8 10 0.009 0.0075
TABLE 5. SERPINA1RiskFactorHaplotypes
SNPNo
Haplotypes 1 2 3 4 6 7 8 10 % inCOPD % in controls P-valuea Odds ratio 95% CI
5-SNP T C A C G 1.61% 0.26% 0.0002 6.2 2.5^17.9
6-SNP T T C A C G 1.55% 0.06% 0.0007 29.8 4.2^210.8
6-SNP T C A A C G 1.45% 0.25% 0.0003 6.3 2.3^17.3
7-SNP T T C A A C G 1.40% 0.06% 0.0009 26.2 3.8^181.4
7-SNP T T C A T C G 1.46% 0.04% 0.0024 44.5 3.9^514.4
8-SNP T T C A T A C G 1.32% 0.03% 0.0046 50.3 3.3^758.7
aP-values, odds ratio, and con¢dence intervals are corrected by logistic regression for age, gender, center, and smoking.
CI, con¢dence interval.
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haplotype with specific variants at the other sites incrementally
increasing the odds ratio. None of the at-risk haplotypes are
common to the Z variant [Chappell et al., 2004]. While the
haplotype frequencies are relatively small, the differences between
cases and controls are highly significant, and for a common
complex disease such as COPD they constitute a major risk.
When the same staged process was applied to the analysis of
SERPINA3 SNPs, none of the potential SNP combinations were
found to be associated with disease. This provides strong evidence
that variation in SERPINA3 is not associated with significant risk
of development of COPD, though a minor effect on phenotype
cannot be excluded.
In assessing these results, the potential effects of population
stratification and false positives must be considered. We have no
evidence of stratification in our data. Our use of cohorts with
controls from the same population also confers a high degree of
confidence that stratification was not a contributing factor in our
results. In addition, any imbalance in COPD and control numbers
within centers was corrected for with the use of logistic regression.
Several factors can contribute to false positives in genetic
studies, including coalescent effects of genetic and environmental
background, population substructure, and multiple susceptibility
alleles. It is also possible to miss real associations due to the
heterogeneity that underlies common variants. In the light of
previous evidence for involvement of the SERPINA1 gene in
susceptibility to COPD, this model-free, staged statistical
approach, combined with the use of high-density SNP maps in a
large sample with good phenotypic data, was designed to minimize
the likelihood of false positives. Correction for major confounders
should further unmask cryptic genetic backgrounds that
contribute to susceptibility. However, replication in similar or
larger independent population samples is required to verify
true association.
There is some evidence that the SNPs contributing to the at-
risk haplotype may reflect differences in function. We previously
showed in reporter gene studies that haplotypes containing
SERPINA1 SNPs 1 and 2 are functional [Chappell et al., 2004]
and that the minor allele variant for SNP 10 is associated with
blunted responses to cytokines in a cell transfection system
[Morgan et al., 1993, 1997]. Thus, three of the five SNPs common
to all risk factor haplotypes occur in regions that have functional
significance. This strongly suggests the possibility that the
susceptibility haplotypes may reflect differences in SERPINA1
expression, either in the basal state or in response to cytokines
such as interleukin-6 and oncostatin-M. Cytokines can increase
expression of SERPINA1 up to 100-fold in lung epithelial cells
[Boutten et al., 1998]. Such stimulated local production may be
important for controlling proteolysis in the lung in response to
smoking. Although we cannot completely exclude the possibility
that the haplotypes of SERPINA1 are in linkage disequilibrium
with other neighboring genes, that seems unlikely given the role of
this gene in COPD, and previous data on linkage disequilibrium
for this gene [Chappell et al., 2004].
Many previously reported studies on genetic susceptibility in
COPD were hampered by relatively small population sizes
and difficulties in replication [Joos et al., 2002]. We have
identified new susceptibility haplotypes of SERPINA1 that are
independent of severe deficiency, and confer a similar or higher
risk of COPD than known genetic risk factors in the gene. By
comparison, when corrected for confounders, no increased risk for
COPD was found with the S variant, which results in mild
deficiency. This is consistent with previous reports [Sandford
et al., 1999].
The haplotypes of SERPINA1 identified in this study occur at a
frequency similar to that of the Z variant, but have higher odds
ratios for disease than possession of the Z allele. These findings
highlight the role of specific haplotypes of SERPINA1 that confer
risk to COPD, and further emphasize the key role of SERPINA1 in
this disease.
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